<p>LFMD 投资者如有损失，请在 10 月 27 日截止日期前联系该公司</p>
<p>, /PRNewswire/ -- 一项针对 <strong>LifeMD (NASDAQ: LFMD)</strong> 的新的联邦证券欺诈集体诉讼已被提起，指控该远程医疗公司及其高管向投资者提供了误导性的财务健康和增长前景。该诉讼在纽约东区提起，发生在公司财报发布后，股价在八月份剧烈下跌。</p>
<p>该公司敦促在 LifeMD 投资并遭受重大损失的投资者立即提交您的损失。</p>
<p>** 集体诉讼期间：**2025 年 5 月 7 日–2025 年 8 月 5 日</p>
<p>** 主原告截止日期：**2025 年 10 月 27 日</p>
<p><strong>访问：</strong> www.hbsslaw.com/investor-fraud/lfmd</p>
<p><strong>立即联系该公司：</strong>[email protected]</p>
<p><strong>844-916-0895</strong></p>
<p><strong>LifeMD, Inc. (LFMD) 证券集体诉讼：</strong></p>
<p>该诉讼标题为 <em>Johnston v. LifeMD, Inc.</em>，重点关注 2025 年 5 月 7 日至 8 月 5 日期间。诉讼指控 LifeMD 发布了虚假和误导性声明，特别是在 2025 年 5 月 6 日，当时公司发布了第一季度业绩并提高了全年收入和调整后 EBITDA 指引。投诉称，公司乐观的前景，引用了虚拟肥胖护理中的 “定义类别的竞争护城河” 和其 RexMD 品牌的强劲表现，是虚假的，因为它误导性地未能考虑到关键的业务挑战。</p>
<p>诉讼认为，LifeMD 在其 RexMD 部门面临客户获取成本上升和体重管理业务中退款率高于预期的问题，而这些问题在当时并未向投资者披露。</p>
<p>这一欺诈行为在 2025 年 8 月 5 日曝光，当时 LifeMD 宣布其第二季度业绩，未能达到收入和每股收益预期，并随后大幅下调全年指引。在财报电话会议中，管理层提到其 RexMD 业务的 “暂时性客户获取成本上升” 和体重管理产品的患者退款问题。次日，LifeMD 的股价暴跌超过 44%。</p>
<p>对于在此期间遭受重大损失的投资者而言，该诉讼代表了一个索赔的机会。</p>
<p><strong>Hagens Berman 的调查</strong></p>
<p>Hagens Berman 是一家全国性的原告权利律师事务所，正在调查这些指控。</p>
<p>“我们正在调查 LifeMD 是否知道但未披露关键的运营问题，” Hagens Berman 的合伙人 Reed Kathrein 说。</p>
<p>如果您投资了 LifeMD 并遭受了重大损失，或者您有可能帮助该公司调查的信息，请立即提交您的损失 »</p>
<p>如果您想了解更多信息以及关于 LifeMD 案件和我们调查的常见问题的答案，请阅读更多 »</p>
<p><strong>举报人：</strong> 了解 LifeMD 非公开信息的人员应考虑他们的选择，以帮助调查或利用 SEC 举报人计划。在新计划下，提供原始信息的举报人可能会获得 SEC 成功追回的任何金额的最高 30% 的奖励。有关更多信息，请致电 Reed Kathrein，电话 <strong>844-916-0895</strong> 或发送电子邮件至 [email protected]。</p>
<p>关于 Hagens Berman</p>
<p>Hagens Berman 是一家全球性的原告权利复杂诉讼事务所，专注于企业问责制。该公司拥有强大的业务，代表投资者、举报人、工人、消费者及其他在因企业疏忽和其他不当行为而受到伤害的案件中取得实际结果。Hagens Berman 的团队在该法律领域已获得超过 29 亿美元的赔偿。有关该公司及其成功的更多信息，请访问 hbsslaw.com。关注该公司以获取更新和新闻，账号为 @ClassActionLaw。</p>
<p>来源 Hagens Berman Sobol Shapiro LLP</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMDE0Jk5ld3NJdGVtSWQ9U0Y5Njk2NyZUcmFuc21pc3Npb25fSWQ9MjAyNTEwMTQxMDI2UFJfTkVXU19VU1BSX19fX19TRjk2OTY3?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMDE0Jk5ld3NJdGVtSWQ9U0Y5Njk2NyZUcmFuc21pc3Npb25fSWQ9MjAyNTEwMTQxMDI2UFJfTkVXU19VU1BSX19fX19TRjk2OTY3"/></p>

LFMD

<p>一项针对 LifeMD (NASDAQ: LFMD) 的联邦证券欺诈集体诉讼已被提起，指控其对财务健康和增长前景发表了误导性声明。该诉讼是在公司 8 月份的财报发布后，股价大幅下跌之后提出的。投资者被鼓励在 10 月 27 日截止日期之前联系 Hagens Berman，以追回在 2025 年 5 月 7 日至 8 月 5 日期间遭受的损失。诉讼称 LifeMD 未能披露客户获取成本上升和退款问题，导致在令人失望的第二季度业绩发布后，股价下跌了 44%</p>

<p>LFMD Investors with Losses Encouraged to Contact the Firm Before Oct. 27th Deadline</p>
<div class="lb-trans"><p>LFMD 投资者如有损失，请在 10 月 27 日截止日期前联系该公司</p>
</div><p>, /PRNewswire/ -- A new federal securities fraud class action lawsuit has been filed against <strong>LifeMD (NASDAQ: LFMD)</strong>, alleging that the telehealth company and its executives provided investors with a misleading picture of its financial health and growth prospects. The suit, filed in in the Eastern District of New York, comes after a dramatic stock price decline in August following the company's earnings report.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- 一项针对 <strong>LifeMD (NASDAQ: LFMD)</strong> 的新的联邦证券欺诈集体诉讼已被提起，指控该远程医疗公司及其高管向投资者提供了误导性的财务健康和增长前景。该诉讼在纽约东区提起，发生在公司财报发布后，股价在八月份剧烈下跌。</p>
</div><p>The firm urges investors in LifeMD who suffered significant losses to submit your losses now.</p>
<div class="lb-trans"><p>该公司敦促在 LifeMD 投资并遭受重大损失的投资者立即提交您的损失。</p>
</div><p><strong>Class Period:</strong> May 7, 2025 – Aug. 5, 2025</p>
<div class="lb-trans"><p>** 集体诉讼期间：**2025 年 5 月 7 日–2025 年 8 月 5 日</p>
</div><p><strong>Lead Plaintiff Deadline:</strong> Oct. 27, 2025</p>
<div class="lb-trans"><p>** 主原告截止日期：**2025 年 10 月 27 日</p>
</div><p><strong>Visit:</strong> www.hbsslaw.com/investor-fraud/lfmd</p>
<div class="lb-trans"><p><strong>访问：</strong> www.hbsslaw.com/investor-fraud/lfmd</p>
</div><p><strong>Contact the Firm Now:</strong>[email protected]</p>
<div class="lb-trans"><p><strong>立即联系该公司：</strong>[email protected]</p>
</div><p><strong>844-916-0895</strong></p>
<div class="lb-trans"><p><strong>844-916-0895</strong></p>
</div><p><strong>LifeMD, Inc. (LFMD) Securities Class Action:</strong></p>
<div class="lb-trans"><p><strong>LifeMD, Inc. (LFMD) 证券集体诉讼：</strong></p>
</div><p>The lawsuit, captioned <em>Johnston v. LifeMD, Inc.</em>, focuses on the period between May 7 and August 5, 2025. It alleges that LifeMD made false and misleading statements, particularly on May 6, 2025, when it reported its first-quarter results and raised its full-year revenue and adjusted EBITDA guidance. The complaint claims that the company's optimistic outlook, which cited a &#34;category-defining competitive moat&#34; in virtual obesity care and strong performance from its RexMD brand, was false as it misleadingly failed to account for crucial business challenges.</p>
<div class="lb-trans"><p>该诉讼标题为 <em>Johnston v. LifeMD, Inc.</em>，重点关注 2025 年 5 月 7 日至 8 月 5 日期间。诉讼指控 LifeMD 发布了虚假和误导性声明，特别是在 2025 年 5 月 6 日，当时公司发布了第一季度业绩并提高了全年收入和调整后 EBITDA 指引。投诉称，公司乐观的前景，引用了虚拟肥胖护理中的 “定义类别的竞争护城河” 和其 RexMD 品牌的强劲表现，是虚假的，因为它误导性地未能考虑到关键的业务挑战。</p>
</div><p>The suit contends that LifeMD was experiencing rising customer acquisition costs in its RexMD segment and a higher-than-anticipated refund rate in its weight management business, issues that it did not disclose to investors at the time.</p>
<div class="lb-trans"><p>诉讼认为，LifeMD 在其 RexMD 部门面临客户获取成本上升和体重管理业务中退款率高于预期的问题，而这些问题在当时并未向投资者披露。</p>
</div><p>The alleged deception unraveled on August 5, 2025, when LifeMD announced its second-quarter results, missing revenue and earnings per share estimates and subsequently slashing its full-year guidance. During the earnings call, management cited &#34;temporary elevated customer acquisition costs&#34; for its RexMD business and issues with patient refunds for its weight management offerings. The following day, LifeMD's stock price plummeted by over 44%.</p>
<div class="lb-trans"><p>这一欺诈行为在 2025 年 8 月 5 日曝光，当时 LifeMD 宣布其第二季度业绩，未能达到收入和每股收益预期，并随后大幅下调全年指引。在财报电话会议中，管理层提到其 RexMD 业务的 “暂时性客户获取成本上升” 和体重管理产品的患者退款问题。次日，LifeMD 的股价暴跌超过 44%。</p>
</div><p>For investors who suffered substantial losses during this period, the lawsuit represents an opportunity to recover damages.</p>
<div class="lb-trans"><p>对于在此期间遭受重大损失的投资者而言，该诉讼代表了一个索赔的机会。</p>
</div><p><strong>Hagens Berman's Investigation</strong></p>
<div class="lb-trans"><p><strong>Hagens Berman 的调查</strong></p>
</div><p>Hagens Berman, a national plaintiffs' rights firm, is investigating these claims.</p>
<div class="lb-trans"><p>Hagens Berman 是一家全国性的原告权利律师事务所，正在调查这些指控。</p>
</div><p>&#34;We're investigating whether LifeMD knew of but failed to disclose key operational problems,&#34; said Reed Kathrein, the Hagens Berman partner leading the investigation.</p>
<div class="lb-trans"><p>“我们正在调查 LifeMD 是否知道但未披露关键的运营问题，” Hagens Berman 的合伙人 Reed Kathrein 说。</p>
</div><p>If you invested in LifeMD and have substantial losses, or have knowledge that may assist the firm's investigation, submit your losses now »</p>
<div class="lb-trans"><p>如果您投资了 LifeMD 并遭受了重大损失，或者您有可能帮助该公司调查的信息，请立即提交您的损失 »</p>
</div><p>If you'd like more information and answers to frequently asked questions about the LifeMD case and our investigation, read more »</p>
<div class="lb-trans"><p>如果您想了解更多信息以及关于 LifeMD 案件和我们调查的常见问题的答案，请阅读更多 »</p>
</div><p><strong>Whistleblowers:</strong> Persons with non-public information regarding LifeMD should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at <strong>844-916-0895</strong> or email [email protected].</p>
<div class="lb-trans"><p><strong>举报人：</strong> 了解 LifeMD 非公开信息的人员应考虑他们的选择，以帮助调查或利用 SEC 举报人计划。在新计划下，提供原始信息的举报人可能会获得 SEC 成功追回的任何金额的最高 30% 的奖励。有关更多信息，请致电 Reed Kathrein，电话 <strong>844-916-0895</strong> 或发送电子邮件至 [email protected]。</p>
</div><p>About Hagens Berman</p>
<div class="lb-trans"><p>关于 Hagens Berman</p>
</div><p>Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.</p>
<div class="lb-trans"><p>Hagens Berman 是一家全球性的原告权利复杂诉讼事务所，专注于企业问责制。该公司拥有强大的业务，代表投资者、举报人、工人、消费者及其他在因企业疏忽和其他不当行为而受到伤害的案件中取得实际结果。Hagens Berman 的团队在该法律领域已获得超过 29 亿美元的赔偿。有关该公司及其成功的更多信息，请访问 hbsslaw.com。关注该公司以获取更新和新闻，账号为 @ClassActionLaw。</p>
</div><p>SOURCE Hagens Berman Sobol Shapiro LLP</p>
<div class="lb-trans"><p>来源 Hagens Berman Sobol Shapiro LLP</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMDE0Jk5ld3NJdGVtSWQ9U0Y5Njk2NyZUcmFuc21pc3Npb25fSWQ9MjAyNTEwMTQxMDI2UFJfTkVXU19VU1BSX19fX19TRjk2OTY3" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=SF96967&amp;Transmission_Id=202510141026PR_NEWS_USPR_____SF96967&amp;DateId=20251014"/></p>

LFMD 13 天截止日期警报：诉讼指控远程医疗公司 LifeMD（LFMD）涉嫌误导性陈述 -- Hagens Berman